QURE(QURE)
QURE
ANALYST COVERAGE37 analysts
BUY
▲ +41.4%upside to target
L $10.00
Med $35.00consensus
H $60.00PRICE
Prev Close
24.60
Open
24.27
Day Range24.14 – 25.29
24.14
25.29
52W Range8.73 – 71.50
8.73
71.50
26% of range
VOLUME & SIZE
Avg Volume
3.3M
FUNDAMENTALS
P/E Ratio
-7.1x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.50
High vol
TECHNICAL
RSI (14)
58
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 22
DEx-Dividend
In 90 days
Aug 19
PDividend Pay
In 97 days
Aug 26
QURE News
About
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases.
Richard PorterChief Business & Scientific Officer
Chiara Elizabeth RussoSenior Director of Investor Relations
Erin BoyerChief People & Culture Officer
Kylie O'KeefeChief Customer & Strategy Officer
Amin AbujoubChief Technical Operations Officer
Jeannette PottsChief Legal & Compliance Officer and Corporate Secretary
Tamara TugalBusiness Development Director
Walid Abi-SaabChief Medical Officer
Christian KlemtChief Financial Officer, Principal Financial Officer & GM of Amsterdam Site
Matthew Craig KapustaChief Executive Officer & Executive Director
Hugo KatusChairman of Scientific Advisory Board and Managing Director of UniQure-Germany